Abatacept (BR-96 or CTLA4-Ig) is the fi rst biologic discovered internally by Bristol-Myers Squibb (BMS) and, if approved, would be first in a new class of immunosuppressants – selective T-cell costimulation modulators – for the treatment of rheumatoid arthritis (RA).